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HbA1cAbstract Background: Adolescence is a transitional phase characterized by multiple physiological
and psychosocial factors that make glycemic control more difﬁcult, and often results in hyper-
glycemia and/or hypoglycemia-related emergencies, and increases the risk of chronic complications.
Insulin analogs were introduced with the aim of overcoming such difﬁculties.
Objective: To study the role of long acting insulin analog (insulin glargine) in glycemic control of
adolescents with poorly controlled type 1 diabetes who suffer from frequent hypoglycemic attacks
and marked glucose variability, and to compare its effectiveness and cost versus intermediate acting
insulin (NPH) in a country with limited resources like Egypt.
Subject and method: A non-randomized open label treat to target trial that included twenty-nine
adolescents (10–18 years), with T1DM. They were on MDI regimen. All had unsatisfactory glyce-
mic control with frequent hypoglycemia and/or recurrent glucose excursions. All were shifted from
twice daily NPH to single bedtime injection of insulin glargine (Lantus), and followed up for
a minimum period of 6 months.
Results: Switching to insulin glargine was associated with a statistically signiﬁcant reduction in
attacks of hypoglycemia and DKA (p< 0.001), but with insigniﬁcant reduction in HbA1c
(p= 0.9). BMI showed a signiﬁcant increase (p= 0.004), as well as the cost of basal insulin as
glargine compared to NPH.
Conclusion: The present study encourages the use of insulin glargine in the presence of signiﬁcant
hypoglycemia and glucose variability, with close monitoring of diet and weight. Cost effectiveness
and effect on HbA1c and quality of life need further longitudinal studies with larger numbers.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Background
Despite 85 years of research since Banting and Best’s isolation
of insulin-containing extracts, diabetes remains one of the
most important causes of morbidity and mortality in
the world, and its global impact is likely to accelerate over
the coming decades.1
36 H.M. Mona et al.IDF’s most recent estimates indicate that the number of
people less than 25 years with diabetes exceeding 592 million,
in addition to the cases who are currently undiagnosed with
the majority of the number affected living in low- and
middle-income countries. The number of people who develop
type 1 diabetes is increasing. The reasons for this are still
unclear.2
Irrespective of the type of diabetes it is important that man-
agement programs are individualized.3 The introduction of
longer-acting and rapid-acting insulin analogs permits greater
ﬂexibility, better control especially in adolescents. Severe hypo-
glycemia may be experienced during adolescence due to poor
metabolic control exacerbated by irregularities of lifestyle
and risk taking behavior.4,5
The major problem in achieving good glycemic control in
adolescence is the nearly threefold incidence of severe hypo-
glycemia associated with intensive treatment.6 Asymptomatic
hypoglycemia is a common problem in pediatric patients with
type 1 diabetes. Prevalence rates of nocturnal hypoglycemia up
to 70% in children and 50% in adolescents have been
reported.7
Basal insulin analog shows a more predictable insulin effect
with less day to day variation, compared to NPH insulin.8 In
most countries, basal analogs have not been formally
approved for children below the age of 6 years. However, there
is a report of successful use of glargine in children from 1 to
5 years of age,9,10 and started to be available in school health
insurance in Egypt in 2009 with up to 50% cost coverage.
Objectives
To study the role of long acting insulin analog (insulin glar-
gine) in glycemic control of adolescents with poorly controlled
type 1 diabetes who suffer from frequent hypoglycemic attacks
and marked glucose variability, and to compare its effective-
ness and cost versus intermediate acting insulin (NPH) in a
country with limited resources like Egypt.
Material and methods
Study population
The current non-randomized open label treat to target trial
was conducted on 29 adolescents over a period of 6 months.
Subjects had type 1 diabetes mellitus (T1DM) for one year
or more and were on multiple daily insulin injections (MDI)
with unsatisfactory glycemic control. Exclusion criteria were
non-compliant patients coming from remote areas and those
who had not received diabetes education. Two male patients
discontinued the treatment with insulin glargine, one found
it expensive and un-affordable and the second found it ineffec-
tive as he was still suffering from severe glucose excursions. So
the data of 27 patients, 15 females and 12 males were statisti-
cally analyzed.
Procedures
Detailed history included the current age and detailed medical
and family history. All patients were subjected to thorough
clinical examination laying stress on height, weight and BMI.Records were revised for evidence of diabetes complications
and medications other than insulin. After obtaining an
informed written consent from the adolescents and their
guardian(s), all included patients were shifted from twice daily
NPH injections to single bedtime injection of insulin glargine
(Lantus). The total dose of basal insulin (NPH) was decreased
by 20% to prevent hypoglycemia. The required dose was
titrated and guided by the early morning pre-meal blood glu-
cose level tested by glucometer. Dose was increased only after
waiting for 3 days as it takes 2–4 days to reach steady levels10
and doses of rapidly acting insulin were adjusted according to
levels of blood glucose by SMBG. All patients were followed
up every 2 weeks to adjust doses and advise about diet and
exercise for a minimum period of 6 months. Number of attacks
of DKA or hypoglycemia was recorded. The target blood
glucose for fasting and pre-prandial levels was 90–120 mg/dl
and for bed-time or post-prandial levels was 140–160 mg/dl.
As for HbA1c we aimed to achieve levels less than 8% for
10–12 year old patients, and less than 7.5% for patients
above 12 years. The study protocol received approval of the
research ethics committee of the pediatric department at
Cairo University.
Statistical analysis
Collected data were coded, tabulated, and statistically ana-
lyzed using SPSS program (Statistical Package for Social
Sciences) software version 18.0. Descriptive statistics were
done for numerical parametric data while categorical data
were described in terms of mean ± standard deviation
(±SD) and minimum & maximum of the range. p values less
than 0.05 were considered statistically signiﬁcant.Results
The 27 patients included 12 males and 15 females, their mean
age was 12.9 ± 2.6 years (range 10–18 years), and their mean
duration of diabetes was 6.6 ± 2.6 years (range 1–18 years).
Regarding the associated conditions and complications; two
patients had intermittent micro-albuminuria, two had dyslipi-
demia, one was on L-thyroxin for hypothyroidism and one had
bronchial asthma but was not on systemic steroids.
Statistical analyses of patients’ data before and after switch-
ing to insulin glargine are summarized in Table 1. There was
signiﬁcant decline in the number of DKA and hypoglycemic
attacks and the basal insulin daily requirements. There was a
signiﬁcant increase in the mean BMI and the total monthly
cost of basal insulin. Individual data of the 27 patients
included in the study revealed no change of BMI in 4 patients
and 5–12% increase in BMI of 23 patients. Mean HbA1c did
not show signiﬁcant change after 6 month use of insulin
glargine.
The patients obtained insulin glargine from different
sources; mainly from their school health insurance system
where they have to pay 50% of the price of insulin glargine.
Second most frequent source was DEMPU clinic at the
Children hospital of Cairo University where the supplies of
insulin glargine are dependent on donations. This makes the
constant availability of insulin glargine among the patients
inconsistent.
Table 1 Comparison of BMI, DKA, hypoglycemia, HbA1c, total and basal insulin dose and the cost at basal and end points.
Basal point mean ± SD (range) End point mean ± SD (range) p-Value
BMI (kg/m2) 19.1 ± 2.27 (15.9–23.6) 20.8 ± 2.52 (16.7–26) 0.004*
Number of ketonuria/6 months 0.96 ± 0.76 (0–3) 0.07 ± 0.26 (0–1) <0.001*
Number of hypoglycemic attacks/month 17.48 ± 11.26 (0–28) 1.51 ± 2.42 (0–8) <0.001*
HbA1c (%) 8.06 ± 1.65 (5.3–12) 8 ± 0.99 (6.2–10.2) 0.9
Total insulin dose (IU/kg/day) 1.2 ± 0.36 (0.5–2) 1.12 ± 0.42 (0.4–2.2) 0.098
Dose of basal insulin (IU/kg/day) 0.52 ± 0.24 (0.2–1) 0.39 ± 0.17 (0.1–0.8) 0.007*
Cost of basal insulin (LE/month) 75.67 ± 29.89 (14–140) 146.41 ± 60.99 (34–255) <0.001*
BMI: body mass index, HbA1c: glycosylated hemoglobin.
* Statistically signiﬁcant.
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In the present study, there was a signiﬁcant decline in the num-
ber of hypoglycemic attacks (p< 0.001). This is in agreement
with Colino et al. and Deiss et al. who found decreased
severe and nocturnal hypoglycemia with the use of
insulin glargine.7,11 However, Chase et al. and Pa¨iva¨rinta
et al., found comparable rates of hypoglycemia between
patients treated with NPH and glargine.12,13 This difference
may be attributed to different targets of glycemic control
across these studies.
The present study also revealed a signiﬁcant decline in the
number of DKA attacks (p< 0.001) after switching to insulin
glargine. This result is in line with Yagasaki et al. who found
more stable blood glucose level with less frequent ketonuria.14
In the current study, there was insigniﬁcant improvement in
the glycosylated hemoglobin (p-value 0.9) after switching to
glargine. This ﬁnding is in line with the ﬁnding of Schober
et al. and Chase et al., who found a signiﬁcant drop in fasting
glucose levels, but the drop in hemoglobin A1c was not
signiﬁcant.12,15
Reviews of insulin analog studies have not found marked
overall improvement in glycosylated hemoglobin (HbA1c) out-
comes compared to traditional human insulin, although they
were associated with signiﬁcantly lower HbA1c compared to
the basal bolus regimens. The monitoring of HbA1c levels
has become a standard measure for evaluating individual treat-
ment success and compliance. However, HbA1c is clearly inﬂu-
enced by indices of glucose tolerance such as fasting and
postprandial plasma glucose (PPG), although the relative
inﬂuence of each factor on HbA1c continues to be debated.
The discrepancy between studies in this ﬁeld might be
explained by the fact that the relative contribution of PPG
to HbA1c may predominate in relatively well-controlled
patients, whereas FPG may come to predominate as the dis-
ease worsens.1 Biological variation in A1C alleles may also
play a signiﬁcant role in determining HbA1c glycosylation
levels.16 Beyond HbA1c comparisons, insulin analogs were
associated with lower risks of hypoglycemia, lower levels of
postprandial glucose excursions, better patient adherence,
greater quality of life, and higher satisfaction with insulin ana-
log treatment.1
In the current work, BMI was found to increase signiﬁ-
cantly after the use of insulin glargine (p= 0.004).
Individual data revealed no change in BMI in 4 patients and
5–12% increase in 23 patients. Two adolescents had an
increase of BMI above 85th centile after the use of glargine.Previous studies reported controversial results regarding effect
of insulin glargine on BMI. Some investigators found a signif-
icant increase in BMI with insulin glargine,17,18 while others
reported that insulin glargine was associated with less weight
gain compared with NPH.19 Another study showed that the
mean relative weight for height remained relatively unchanged
during the glargine treatment.13 The increase in BMI was
attributed to the improved metabolic control and anabolic
effect of insulin glargine as it has up to 6-fold greater potency
at the insulin-like growth factor-1 (IGF-1) receptor than regu-
lar human insulin.17,20
Although the quality of life was not assessed in the current
study, there was in general psychological satisfaction with glar-
gine compared to NPH, less frequency of hypoglycemia espe-
cially nocturnal events, less number of admissions to hospital
and better school attendance and performance. Mothers of
some patients described this impressive result by claiming that
they could sleep safely without fearing that their children
might develop nocturnal hypoglycemia. It has been previously
suggested that the ﬂexibility of the glargine regimen, mainly
deﬁned by easier planning of meals, exercise, and deviation
from daily routines, was especially appreciated by the patients
and their parents.13
Regarding the ﬁnancial burden of insulin glargine, the
study revealed the signiﬁcantly higher cost of insulin glargine
compared to NPH. They obtained insulin glargine from vari-
able sources, but the availability of insulin glargine among
the patients was inconsistent. This makes the ability of
adolescents at DEMPU with type 1 diabetes inconsistent to
get insulin glargine.
The results of the present study encourage the use of insulin
glargine in the presence of signiﬁcant hypoglycemia and glu-
cose variability, with close monitoring of diet and weight to
avoid undesirable weight gain. Cost effectiveness and effect
on HbA1c and quality of life need further longitudinal studies
with larger numbers.
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